Literature DB >> 25061164

Carfilzomib: a new opportunity for WM patients.

Enrica Morra1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25061164      PMCID： PMC4110649          DOI： 10.1182/blood-2014-06-578625

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

Authors:  Meletios A Dimopoulos; Athanasios Anagnostopoulos; Maria Christina Kyrtsonis; Efstathios Castritis; Athanasios Bitsaktsis; Gerassimos A Pangalis
Journal:  Haematologica       Date:  2005-12       Impact factor: 9.941

2.  Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Sandra Kanan; Patricia Sheehy; Stacey Chuma; Lian Xu; Yang Cao; Guang Yang; Xia Liu; Christopher J Patterson; Diane Warren; Zachary R Hunter; Barry Turnbull; Irene M Ghobrial; Jorge J Castillo
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

3.  Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.

Authors:  Steven P Treon; Guang Yang; Christine Hanzis; Leukothea Ioakimidis; Sigitas J Verselis; Edward A Fox; Lian Xu; Zachary R Hunter; Hsiuyi Tseng; Robert J Manning; Christopher J Patterson; Patricia Sheehy; Barry Turnbull
Journal:  Br J Haematol       Date:  2011-05-12       Impact factor: 6.998

4.  Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

Authors:  Meletios A Dimopoulos; Ramón García-Sanz; Maria Gavriatopoulou; Pierre Morel; Marie-Christine Kyrtsonis; Eurydiki Michalis; Zafiris Kartasis; Xavier Leleu; Giovanni Palladini; Alessandra Tedeschi; Dimitra Gika; Giampaolo Merlini; Efstathios Kastritis; Pieter Sonneveld
Journal:  Blood       Date:  2013-09-04       Impact factor: 22.113

5.  Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Christine I Chen; C Tom Kouroukis; Darrell White; Michael Voralia; Edward Stadtmauer; A Keith Stewart; John J Wright; Jean Powers; Wendy Walsh; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2007-03-12       Impact factor: 44.544

6.  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

Authors:  Steven P Treon; Yang Cao; Lian Xu; Guang Yang; Xia Liu; Zachary R Hunter
Journal:  Blood       Date:  2014-02-19       Impact factor: 22.113

7.  IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.

Authors:  Zachary R Hunter; Robert J Manning; Christine Hanzis; Bryan T Ciccarelli; Leukothea Ioakimidis; Christopher J Patterson; Megan C Lewicki; Hsuiyi Tseng; Ping Gong; Xia Liu; Yangsheng Zhou; Guang Yang; Jenny Sun; Lian Xu; Patricia Sheehy; Massimo Morra; Steven P Treon
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

8.  Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Authors:  Steven P Treon; Leukothea Ioakimidis; Jacob D Soumerai; Christopher J Patterson; Patricia Sheehy; Marybeth Nelson; Michael Willen; Jeffrey Matous; John Mattern; Jakow G Diener; George P Keogh; Thomas J Myers; Andy Boral; Ann Birner; Dixie L Esseltine; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

9.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Authors:  David Siegel; Thomas Martin; Ajay Nooka; R Donald Harvey; Ravi Vij; Ruben Niesvizky; Ashraf Z Badros; Sundar Jagannath; Leanne McCulloch; Kanya Rajangam; Sagar Lonial
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941
  9 in total
  2 in total

Review 1.  [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].

Authors:  A Grunenberg; C Buske
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

2.  YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways.

Authors:  Bingjie Xue; Wei Huang; Xia Yuan; Bo Xu; Yaxin Lou; Quan Zhou; Fuxiang Ran; Zemei Ge; Runtao Li; Jingrong Cui
Journal:  J Cancer       Date:  2015-02-06       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.